Stereotactic body radiation therapy for operable early-stage lung cancer: Findings from the NRG Oncology RTOG 0618 trial

JAMATimmerman RD, et al. | October 08, 2018

Advertisement

In this single-arm phase 2 NRG Oncology Radiation Therapy Oncology Group 0618 study, researchers investigated the safety of noninvasive stereotactic body radiation therapy (SBRT) delivered on an outpatient basis in eradicating lung cancer. Further, they assessed its efficacy in curing selected patients with operable lung cancer, obviating the need for surgical resection. Findings revealed that, in addition to low treatment-related morbidity, SBRT was associated with a high targeted tumor control such that surgery for salvage was not generally needed. The study results, therefore, support formal comparisons of surgery and stereotactic radiotherapy for early-stage lung cancer.

Read the full article on JAMA

Advertisement